Archives
SAR131675: Potent VEGFR-3 Inhibitor for Fibrosis & Tumor Mod
SAR131675: Precision VEGFR-3 Inhibitor for Preclinical Fibrosis and Tumor Research
Principle Overview: SAR131675 as a Selective VEGFR-3 Inhibitor
SAR131675 stands out as a potent, ATP-competitive inhibitor of vascular endothelial growth factor receptor 3 (VEGFR-3), offering a transformative tool for researchers investigating lymphangiogenesis, angiogenesis, and their roles in pathological conditions such as liver fibrosis and cancer. With an IC50 of 23 nM and a Ki of 12 nM against recombinant human VEGFR-3 kinase, SAR131675 exhibits exceptional selectivity, showing negligible activity against VEGFR-1 (IC50 > 3 μM), minimal inhibition of VEGFR-2 (IC50 235 nM), and no significant off-target effects on a broad spectrum of kinases, enzymes, or ion channels, according to the product information.
As a cell-permeable molecule, SAR131675 efficiently blocks VEGFR-3 autophosphorylation and downstream signaling, thereby inhibiting lymphatic endothelial cell survival and migration driven by VEGFC and VEGFD. This makes it uniquely suited for dissecting the VEGFC–VEGFR-3 axis in models of tissue inflammation, fibrosis, and tumor progression.
Step-by-Step Experimental Workflow: Optimizing SAR131675 Use
To harness the full potential of SAR131675 in preclinical studies, a robust workflow is essential. Below, we outline a streamlined protocol, integrating lessons from recent literature and product specifications.
Protocol Parameters
- In vivo dosing: Administer SAR131675 at 30 mg/kg/day by oral gavage in mice, as applied in NASH-associated fibrosis models (reference study).
- In vitro inhibition: For lymphatic endothelial cell (LEC) assays, use SAR131675 at 14–30 nM to inhibit VEGFC- or VEGFD-induced survival and migration. Incubate for 24–48 hours (product information).
- VEGFR-3 autophosphorylation assays: Apply at 30–50 nM in HEK293 cells expressing recombinant human VEGFR-3, measuring inhibition after 30 minutes of compound exposure.
- Compound solubilization: SAR131675 is insoluble in DMSO, ethanol, and water. Prepare fresh working suspensions using suitable co-solvents or vehicle mixtures (e.g., 0.5% methylcellulose for oral gavage) immediately prior to use; avoid long-term storage of solutions.
Key Innovation from the Reference Study
The recent study by Li et al. (Phytomedicine, 2026) provided compelling evidence that inhibiting the VEGFC–VEGFR-3 axis, either genetically or via pharmacological agents like SAR131675, disrupts a pathologic hepatocyte–macrophage regulatory loop that drives NASH-associated hepatic fibrosis. In high-fat diet (HFD) mouse models, SAR131675 (30 mg/kg/day, oral, 16 weeks) not only reduced hepatic inflammation and fibrosis, but also downregulated VEGFC and CCL2/CCR2 signaling, diminished Ly6Chigh monocyte infiltration, and promoted the resolution of inflammatory macrophage populations.
This mechanistic insight translates into practical assay design: researchers can now model liver fibrosis or inflammation by combining HFD, genetic or pharmacological VEGFR-3 inhibition, and immune cell phenotyping to unravel intercellular crosstalk. It also highlights the value of SAR131675 for studying macrophage migration, phenotypic switching, and the broader immune landscape in metabolic and oncologic disease models.
Advanced Applications and Comparative Advantage
Anti-Lymphangiogenic and Anti-Angiogenic Strategies:
SAR131675’s dual inhibition of lymphangiogenesis and angiogenesis, as shown by its suppression of both VEGFC- and FGF2-stimulated vessel formation, makes it a versatile anti-angiogenic compound. In tumor models, such as 4T1 mammary carcinoma-bearing mice, SAR131675 significantly reduced tumor volume and vessel density, supporting its use for tumor growth inhibition studies (extension article).
Fibrosis and Immune Modulation:
The reference study’s demonstration of SAR131675’s efficacy in preventing hepatic fibrosis via modulation of the VEGFC–VEGFR-3–macrophage axis complements findings from other reports (complementary article) showing that this signaling pathway is a critical node in tissue remodeling and immune cell recruitment. This positions SAR131675 as a strategic anti-lymphangiogenic agent for preclinical fibrosis research.
Benchmark Selectivity:
Compared to earlier VEGFR inhibitors, SAR131675’s minimal off-target profile and nanomolar potency enable precise pathway dissection without confounding effects from VEGFR-1 or other kinases (comparative guide).
Troubleshooting and Optimization Tips
- Compound Handling: Always prepare fresh suspensions due to SAR131675’s insolubility and poor long-term stability in common solvents. Use 0.5% methylcellulose for oral gavage or experiment with compatible vehicles for in vitro application.
- Dose Selection: For in vivo fibrosis or tumor studies, 30 mg/kg/day yields robust target engagement, but titration between 10–50 mg/kg may be warranted depending on model sensitivity and desired endpoint (product information).
- Assay Timing: Allow sufficient time (e.g., 16 weeks for chronic diet models) for fibrosis development before introducing SAR131675 to capture both preventive and therapeutic effects.
- Readout Selection: Pair target engagement assays (e.g., VEGFR-3 phosphorylation, LEC migration) with immune profiling (e.g., Ly6Chigh vs. Ly6Clow macrophages) to fully elucidate SAR131675’s mechanism.
- Control Groups: Always include vehicle and positive control (e.g., genetic knockout or alternative inhibitor) arms to validate specificity.
Why this cross-domain matters, maturity, and limitations
The cross-domain exploration of SAR131675 in both cancer and metabolic liver disease research underscores the centrality of the VEGFC–VEGFR-3 axis in pathological vessel formation and immune modulation. Findings in NASH-associated fibrosis models (reference study) echo those from oncology, where VEGFR-3-driven lymphangiogenesis fuels tumor spread. This convergence validates SAR131675 as a versatile research tool. However, it is important to note that despite promising preclinical results, the clinical development of SAR131675 was discontinued due to adverse metabolic effects, highlighting the need for careful translational consideration and reliance on preclinical endpoints.
Future Outlook
Emerging data, including the pivotal reference study, suggest that targeted disruption of the VEGFC–VEGFR-3 axis could reshape therapeutic strategies for fibrotic diseases and solid tumors. SAR131675 enables rigorous dissection of this pathway in animal and cellular models, paving the way for next-generation anti-lymphangiogenic interventions. As research advances, integration with single-cell profiling, advanced imaging, and combinatorial approaches will further clarify the interplay between endothelial, immune, and stromal compartments. For now, SAR131675, available from APExBIO, remains an indispensable benchmark for experimental modulation of VEGFR-3 signaling in preclinical settings.
For detailed product handling and ordering, visit SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor at APExBIO.